<DOC>
	<DOCNO>NCT02174432</DOCNO>
	<brief_summary>The primary objective study evaluate overall safety nalbuphine HCL ER tablet treatment period 50 week .</brief_summary>
	<brief_title>Open Label Extension Study Nalbuphine HCl ER Patients With Prurigo Nodularis</brief_title>
	<detailed_description />
	<mesh_term>Prurigo</mesh_term>
	<mesh_term>Neurodermatitis</mesh_term>
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Subject complete participation TR03 study Medical condition factor opinion Investigator may interfere conduct study . Subject pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Itch</keyword>
	<keyword>Chronic Itch</keyword>
	<keyword>Nalbupine</keyword>
</DOC>